Loading...
•
Sep 30, 2022
Nkarta Q3 2022 Earnings Report
Nkarta reported financial results for the third quarter ended September 30, 2022.
Key Takeaways
Nkarta reported a net loss of $28.3 million for the third quarter of 2022. As of September 30, 2022, Nkarta had cash, cash equivalents, restricted cash, and short-term investments of $395.1 million.
NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022
NKX019 Phase 1 clinical trial recently opened dose expansion cohorts
Next NKX019 clinical update is expected by year-end 2022
Next NKX101 clinical update is expected in first half of 2023
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...